Zijdenbos Ingeborg L, de Wit Niek J, van der Heijden Geert J, Rubin Gregory, Quartero A Otto
Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Stratenum 6.131, P.O. Box 85500, Utrecht, Netherlands, 3508.
Cochrane Database Syst Rev. 2009 Jan 21(1):CD006442. doi: 10.1002/14651858.CD006442.pub2.
No consensus exists on the optimal treatment for irritable bowel syndrome (IBS). Psychological treatments are increasingly advocated but their effectiveness is unclear.
To evaluate the efficacy of psychological interventions for the treatment of irritable bowel syndrome.
A computer assisted search of MEDLINE, EMBASE, PsychInfo, CINAHL, Web of Science, The Cochrane Library and Google Scholar was performed for the years 1966-2008. Local databases were searched in Europe.
Randomised trials comparing single psychological interventions with either usual care or mock interventions in patients over 16 years of age. No language criterion was applied.
The search identified 25 studies that fulfilled the inclusion criteria. The relative risk (RR), risk difference (RD), number needed to treat (NNT) and standardized mean difference (SMD) along with 95% confidence intervals were calculated using a random effects model for each outcome.
Psychological interventions as a group The SMD for symptom score improvement at 2 and 3 months was 0.97 (95% CI 0.29 to 1.65) and 0.62 (95% CI 0.45 to 0.79) respectively compared to usual care. Against placebo, the SMDs were 0.71 (95% CI 0.08 to 1.33) and -0.17 (95% CI -0.45 to 0.11) respectively. For improvement of abdominal pain, the SMDs at 2 and 3 months were 0.54 (95%CI 0.10 to 0.98) and 0.26 (95% CI 0.07 to 0.45) compared to usual care. The SMD from placebo at 3 months was 0.31 (95% CI -0.16 to 0.79). For improvement in quality of life, the SMD from usual care at 2 and 3 months was 0.47 (95%CI 0.11 to 0.84) and 0.31 (95%CI -0.16 to 0.77) respectively. Cognitive behavioural therapy The SMD for symptom score improvement at 2 and 3 months was 0.75 (95% CI -0.20 to 1.70) and 0.58 (95% CI 0.36 to 0.79) respectively compared to usual care. Against placebo, the SMDs were 0.68 (95% CI -0.01 to 1.36) and -0.17 (95% CI -0.45 to 0.11) respectively. For improvement of abdominal pain, the SMDs at 2 and 3 months were 0.45 (95% CI 0.00 to 0.91) and 0.22 (95% CI -0.04 to -0.49) compared to usual care. Against placebo the SMD at 3 months was 0.33 (95% CI -0.16 to 0.82). For improvement in quality of life, the SMDs at 2 and 3 months compared to usual care were 0.44 (95% CI 0.04 to 0.85) and 0.92 (95% CI 0.07 to 1.77) respectively.Interpersonal psychotherapy The RR for adequate relief of symptoms was 2.02 (95% CI 1.13 to 3.62), RD 0.30 (95% CI 0.13 to 0.46), NNT 4 for comparison with care as usual. The SMD for improvement of symptom score was 0.35 (95% CI -0.75 to 0.05) compared with usual care. Relaxation/Stress management The SMD in symptom score improvement at 2 months was 0.50 (95%CI 0.02 to 0.98) compared with usual care. The SMD in improvement of abdominal pain at 3 months was 0.02 (95%CI -0.56 to 0.61) compared with usual care. Long term results Very few long term follow-up results were available. There was no convincing evidence that treatment effects were sustained following completion of treatment for any treatment modality.
AUTHORS' CONCLUSIONS: Psychological interventions may be slightly superior to usual care or waiting list control conditions at the end of treatment although the clinical significance of this is debatable. Except for a single study, these therapies are not superior to placebo and the sustainability of their effect is questionable. The meta-analysis was significantly limited by issues of validity, heterogeneity, small sample size and outcome definition. Future research should adhere to current recommendations for IBS treatment trials and should focus on the long-term effects of treatment.
对于肠易激综合征(IBS)的最佳治疗方法尚无共识。心理治疗越来越受到推崇,但其有效性尚不清楚。
评估心理干预对治疗肠易激综合征的疗效。
对1966年至2008年期间的MEDLINE、EMBASE、PsychInfo、CINAHL、Web of Science、Cochrane图书馆和谷歌学术进行计算机辅助检索。在欧洲检索了当地数据库。
将单一心理干预与常规护理或模拟干预进行比较的随机试验,受试者年龄超过16岁。未应用语言标准。
检索确定了25项符合纳入标准的研究。使用随机效应模型为每个结果计算相对风险(RR)、风险差(RD)、治疗所需人数(NNT)和标准化均数差(SMD)以及95%置信区间。
心理干预作为一个整体与常规护理相比,2个月和3个月时症状评分改善的SMD分别为0.97(95%CI 0.29至1.65)和0.62(95%CI 0.45至0.79)。与安慰剂相比,SMD分别为0.71(95%CI 0.08至1.33)和-0.17(95%CI -0.45至0.11)。对于腹痛改善,与常规护理相比,2个月和3个月时的SMD分别为0.54(95%CI 0.10至0.98)和0.26(95%CI 0.07至0.45)。3个月时与安慰剂相比的SMD为0.31(95%CI -0.16至0.79)。对于生活质量改善,与常规护理相比,2个月和3个月时的SMD分别为0.47(95%CI 0.11至0.84)和0.31(95%CI -0.16至0.77)。认知行为疗法与常规护理相比,2个月和3个月时症状评分改善的SMD分别为0.75(95%CI -0.20至1.70)和0.58(95%CI 0.36至0.79)。与安慰剂相比,SMD分别为0.68(95%CI -0.01至1.36)和-0.17(95%CI -0.45至0.11)。对于腹痛改善,与常规护理相比,2个月和3个月时的SMD分别为0.45(95%CI 0.00至0.91)和0.22(95%CI -0.04至0.49)。与安慰剂相比,3个月时的SMD为0.33(95%CI -0.16至0.82)。对于生活质量改善,与常规护理相比,2个月和3个月时的SMD分别为0.44(95%CI 0.04至0.85)和0.92(95%CI 0.07至1.77)。人际心理治疗与常规护理相比,症状充分缓解的RR为2.02(95%CI 1.13至3.62),RD为0.30(95%CI 0.13至0.46),NNT为4。与常规护理相比,症状评分改善的SMD为0.35(95%CI -0.75至0.05)。放松/压力管理与常规护理相比,2个月时症状评分改善的SMD为0.50(95%CI 0.02至0.98)。与常规护理相比,3个月时腹痛改善的SMD为0.02(95%CI -0.56至0.61)。长期结果 可获得的长期随访结果非常少。没有令人信服的证据表明任何治疗方式在治疗结束后治疗效果能够持续。
心理干预在治疗结束时可能略优于常规护理或等待名单对照情况,尽管其临床意义存在争议。除了一项研究外,这些疗法并不优于安慰剂,其效果的可持续性也值得怀疑。荟萃分析受到有效性、异质性、样本量小和结果定义等问题的显著限制。未来研究应遵循当前肠易激综合征治疗试验的建议,并应关注治疗的长期效果。